Increased Venture Capital Investment Bolsters Women's Health Startups
- None.
- Valuations dropped in 2023 for women's health companies, and seed stage women's health companies are consistently valued 20% lower than overall healthcare companies at the seed stage.
Insights
The surge in investment for women's health startups, as highlighted by the Silicon Valley Bank report, signals an evolving market landscape. The 314% increase since 2018 contrasts with a more modest 28% growth in the broader health sector, indicating a shift in investor focus. This pivot may reflect a recognition of the untapped market potential within women's health, which has historically been underserved. The emphasis on conditions beyond reproductive health, such as menopause and mental health, suggests a broadening of the sector's scope.
For stakeholders, the immediate impact includes a diversification of investment portfolios and potential for high returns as the market corrects historical undervaluation. However, the noted discrepancy in seed stage valuation poses a risk of persistent undervaluation, which could impact future funding rounds. In the long term, increased data collection and clinical trials could mitigate this risk by solidifying the market size and potential.
The report's focus on the lack of data collection in women's health is a critical point for the sector's future. Insufficient data has implications for clinical trial design, FDA approval processes and ultimately, patient access to innovative treatments. The White House Initiative on Women's Health Research is an encouraging step towards addressing these data gaps. As more data becomes available, we can expect a more robust pipeline of women's health products, which could lead to increased valuations and investor interest.
It's also noteworthy that 76% of women's health companies have a female founder. This could influence company culture, research focus and patient engagement in a positive way, potentially leading to more effective and targeted healthcare solutions for women.
The reported trend of rising investment in women's health is indicative of the market's resilience amidst broader economic challenges. While valuations in 2023 saw a downturn, the long-term view may be optimistic if the sector continues to attract investment at the current rate. The shift in funding towards non-reproductive health startups, with $435 million invested in Q3 2023 alone, points to a maturation of the sector and a diversification of opportunities for investors.
Investors should monitor the upcoming Healthcare Exits and Investments report for insights into M&A activity, IPO trends and overall investment health, which may offer further evidence of the sector's momentum. The high proportion of female-led companies could also be a factor in driving innovation and attracting a diverse investor base.
Silicon Valley Bank Releases First Innovation in Women's Health Report
SVB's Innovation in Women's Health Report examines fundraising and investment activity as well as capital and valuation trends across the sector. The report defines women's health as healthtech, biopharma, diagnostics/tools, and medical device companies that address underserved care needs for women. This includes conditions that uniquely impact women, conditions that differently or disproportionately impact women, and conditions that are marked by gender-based discrepancies in care.
"Despite broader challenges in the larger venture capital landscape, women's health is showing significant momentum and progress," said Raysa Bousleiman, co-author of the SVB Innovation in Women's Health report and VP of Venture Capital Relationship Management for Life Science and Healthcare at SVB. "Investors and companies are challenging the misconception that women's health is restricted to reproductive years and realizing the tremendous opportunity to address the complete spectrum of health needs throughout a woman's life. Investments are increasingly shifting into emerging areas such as menopause, pelvic health and mental health."
Along with other startups, women's health companies saw valuations drop in 2023. Women's health companies are typically valued lower than healthcare companies overall, with seed stage women's health companies consistently valued
"The lack of data on women's health can be a roadblock for founders when convincing investors there is a need for their company, for accurately estimating market size and for receiving FDA approval," said Bousleiman. "However, valuations could increase as investors are encouraged by efforts such as the White House Initiative on Women's Health Research, which aims to close the research gaps in the sector. As clinical trials move forward and more data becomes available, the clinical development of diagnostics, devices and therapeutics to address women's health issues will progress."
Key Report Findings: Innovation and Investment in Women's Health
- With a
314% increase in women's health venture capital investment since 2018, 2023 will rank as a top funding year for the sector - Investments in non-reproduction startups reached
$435 million - Averaging
$182M 76% of women's health companies have a female founder which is three times higher than companies across the overall innovation ecosystem
Delivering relevant insights on the current and future state of the Healthcare market, SVB will next release its 2024 Healthcare Exits and Investments report on January 17th, 2024. This annual report analyzes trends for venture capital investing, fundraising, M&A activity and IPOs for biopharma, medical device, diagnostics and tools, and healthtech sectors in the US and
Bousleiman, and other leaders from SVB's Life Science and Healthcare practice, will preview the 2024 Healthcare Exits and Investments report during the J.P. Morgan Healthcare conference this week in
- Bousleiman will moderate a panel session "Women's Health: A Huge Area Attracting New Investment" as part of the Biotech Showcase
- Ben Johnson, head of Early Stage Life Science and Healthcare, will moderate a panel session "Early Seed Financing: Attracting Investment & Extending Your Runway" as part of the Biotech Showcase
- Scott McCarty, director of Life Science and Healthcare Southeast region, will be speaking on a panel "The State of the Digital Healthcare Industry" as part of the Biotech Showcase
- Jackie Spencer, head of US Relationship Management for Life Science and Healthcare practice, will be speaking on a panel "Crossovers, Megarounds and IPOs: Biotechs Always Find a Way," at Fierce
To access the complete "Innovation in Women's Health report" and to watch SVB's recent webinar featuring investor, founder and researcher perspectives, "Unlocking the Blue Ocean Opportunities in Women's Health," please visit Innovation in Women's Health | Silicon Valley Bank (svb.com)
About Silicon Valley Bank
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world's most innovative companies and investors. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital and premium wine industries. SVB operates in centers of innovation throughout
View original content to download multimedia:https://www.prnewswire.com/news-releases/increased-venture-capital-investment-bolsters-womens-health-startups-302028253.html
SOURCE Silicon Valley Bank
FAQ
What is the key finding of the Silicon Valley Bank (SVB) Innovation in Women's Health Report?
What are some emerging areas of focus for women's health companies according to the report?
What is the percentage of women's health companies with a female founder?
What is the valuation trend for women's health companies in 2023?
What are the future plans for SVB's healthcare reports?
